Tech Company Financing Transactions
Tolremo therapeutics Funding Round
Tolremo therapeutics closed a $39 million Series A funding round on 9/20/2023. Backers included BioMedPartners and Pierre Fabre.
Transaction Overview
Company Name
Announced On
9/20/2023
Transaction Type
Venture Equity
Amount
$39,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate TT125-802 into a first-in-human study in patients with solid tumors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Hochbergerstrasse 60C
Basel, CH-4057
CH
Basel, CH-4057
CH
Phone
Undisclosed
Website
Email Address
Overview
TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stefanie Mangual
Chief Operating Officer
Claudia Escher
Browse more venture capital transactions:
Prev: 9/20/2023: Codee venture capital transaction
Next: 9/20/2023: Vivante Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs